Is NKTR a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

621 people get NKTR articles and Market Currents by email alert.

Get email alerts on NKTR »

HEADLINES:

Nektar Therapeutics' CEO Presents at UBS Global Healthcare Conference (Transcript)
Tue, May 21
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City

PR Newswire (May 16, 2013)
Nektar's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 10
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013

PR Newswire (May 9, 2013)
Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets

PR Newswire (May 2, 2013)
Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013

PR Newswire (Apr 7, 2013)
Several Big Growth Stories In Biotech: Keith Markey
Life Sciences Report • Thu, Mar 28 • 5 Comments
What Is In The Future For Nektar?
C.R. Jackson • Thu, Mar 21 • 1 Comment
Why AstraZeneca Will Disappoint In 2013
Bio Matt • Sun, Mar 17 • 7 Comments
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston

PR Newswire (Mar 1, 2013)
Nektar Therapeutics CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results

PR Newswire (Feb 28, 2013)
4 Drug Delivery Companies That Deliver For Investors
Ryan's View • Wed, Feb 27
AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation

PR Newswire (Feb 26, 2013)
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets

PR Newswire (Feb 13, 2013)
Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC)

PR Newswire (Feb 5, 2013)
Nektar Therapeutics' CEO Presents at JP Morgan Healthcare Conference (Transcript)
Wed, Jan 9
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire (Jan 4, 2013)
Is Zogenix A Buy After FDA Panel Says 'No' To Zohydro?
C.R. Jackson • Fri, Dec 14, 2012 • 15 Comments
Alexza's Adasuve May Not Be Ready For FDA Approval
Beacon VP Investments • Tue, Dec 11, 2012 • 28 Comments

To learn more about Seeking Alpha Pro, click here.

What Is In The Future For Nektar?
C.R. Jackson • Thu, Mar 21 • 1 Comment
Nektar Phase III Trials At Risk
Martin Shkreli • Mon, Jun 18, 2012 • 13 Comments
Nektar Therapeutics: Often Forgotten, But Worth A Look
Stephen Simpson • Mon, Jan 23, 2012 • 3 Comments
Nektar: Sometimes Fundamental Analysis Takes Awhile To Work
SoundView Technology Group • Thu, Nov 15, 2007 • 1 Comment
Cowen Sees Nektar Outperforming Market By 30%+
Notable Calls • Wed, Jun 27, 2007
Nektar Therapeutics: Strong Short Squeeze Candidate
Notable Calls • Thu, May 10, 2007

Several Big Growth Stories In Biotech: Keith Markey
Life Sciences Report • Thu, Mar 28 • 5 Comments
Why AstraZeneca Will Disappoint In 2013
Bio Matt • Sun, Mar 17 • 7 Comments
4 Drug Delivery Companies That Deliver For Investors
Ryan's View • Wed, Feb 27
Is Zogenix A Buy After FDA Panel Says 'No' To Zohydro?
C.R. Jackson • Fri, Dec 14, 2012 • 15 Comments
Alexza's Adasuve May Not Be Ready For FDA Approval
Beacon VP Investments • Tue, Dec 11, 2012 • 28 Comments
2 Healthcare Companies With New Analyst Coverage Growth Investors Should Consider
Matt Schilling • Thu, Aug 30, 2012
How Newly Enacted Legislation Could Rally Small-Cap Biotechs Further
Scott Matusow • Fri, Aug 24, 2012 • 23 Comments
Why M&A Flurry Has Top MKM Analyst Smiling All The Way To The Bank
Life Sciences Report • Thu, Aug 23, 2012
5 Pharmaceutical Companies With Phase III Clinical Study Catalysts During The Next 3 - 9 Months (Part II)
Markus Aarnio • Tue, Aug 21, 2012 • 4 Comments
8 Intriguing Small Cap Biotechnology Companies For Your Consideration
Joe Springer • Mon, Aug 20, 2012 • 2 Comments
Uncertainty Is The Trade-Off For Salix's Appealing Price
Stephen Simpson • Tue, Aug 14, 2012 • 5 Comments
2 Pharma Companies To Consider Ahead Of Earnings
Matt Schilling • Thu, Aug 9, 2012 • 1 Comment
AstraZeneca Taking Its Lumps
Stephen Simpson • Fri, Jul 27, 2012 • 2 Comments
7 Fast Growing Small Cap Biotech Stocks With Analyst Confidence
ZetaKap • Fri, Jul 6, 2012
Cardiovascular Cell Therapies To Put Pressure On U.S. Regulators
Brian Nichols • Thu, Jul 5, 2012 • 12 Comments
Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2
StockPandit • Fri, May 25, 2012 • 1 Comment
Top 5 Biotech ETFs
David Fry • Tue, May 15, 2012 • 5 Comments
5 Hedge Fund Biotech Stock Picks With Significant Short Covering
Kapitall • Tue, Apr 24, 2012
Why The Markets Continue To Coalesce Around New Approaches To Treating Cancer
Brett Korsgaard • Thu, Apr 19, 2012 • 4 Comments
Long Undervalued, Is Alkermes Still A Bargain?
Stephen Simpson • Fri, Mar 30, 2012 • 1 Comment

Nektar Therapeutics' CEO Presents at UBS Global Healthcare Conference (Transcript)
Tue, May 21
Nektar's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Fri, May 10
Nektar Therapeutics CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 28
Nektar Therapeutics' CEO Presents at JP Morgan Healthcare Conference (Transcript)
Wed, Jan 9
Nektar Therapeutics' CEO Discusses Naloxegol Study Results Conference (Transcript)
Mon, Nov 12, 2012
Nektar Therapeutics' CEO Presents at UBS Global Life Sciences Conference - Transcript
Wed, Sep 19, 2012
Nektar Therapeutics' CEO Discusses Q2 2012 Results - Earnings Transcript
Thu, Aug 9, 2012
Nektar CEO Discusses Q3 2010 Results - Earnings Call Transcript
Thu, Nov 4, 2010
Nektar Therapeutics Q2 2010 Earnings Call Transcript
Thu, Jul 29, 2010
Nektar Therapeutics Q1 2010 Earnings Call Transcript
Thu, May 6, 2010
Nektar Therapeutics Q2 2009 Earnings Call Transcript
Tue, Aug 4, 2009
Nektar Therapeutics F4Q08 and Year End 2008 Earnings Call Transcript
Mon, Mar 2, 2009
Nektar Therapeutics, Q4 2008 Earnings Call Transcript
Mon, Mar 2, 2009
Nektar Therapeutics Q3 2008 Earnings Call Transcript
Thu, Nov 20, 2008
Nektar Therapeutics Q2 2008 Earnings Call Transcript
Sat, Aug 9, 2008
Nektar Therapeutics Q1 2008 Earnings Call Transcript
Mon, May 19, 2008
Nektar Therapeutics Q4 2007 Earnings Call Transcript
Mon, Mar 10, 2008

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City

PR Newswire (May 16, 2013)
Nektar Therapeutics Reports Financial Results for the First Quarter of 2013

PR Newswire (May 9, 2013)
Nektar to Announce Financial Results for the First Quarter of 2013 on Thursday, May 9, 2013, After Close of U.S.-Based Financial Markets

PR Newswire (May 2, 2013)
Positive Preclinical Data for NKTR-214, an Investigational Cancer Immunotherapy Targeting the IL-2 Receptor Complex, Presented at AACR Annual Meeting 2013

PR Newswire (Apr 7, 2013)
Nektar Therapeutics to Present at the 33rd Annual Cowen and Company Healthcare Conference in Boston

PR Newswire (Mar 1, 2013)
Nektar Therapeutics Reports Fourth Quarter and Year-End 2012 Financial Results

PR Newswire (Feb 28, 2013)
AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation

PR Newswire (Feb 26, 2013)
Nektar to Announce Financial Results for the Fourth Quarter and Year-End of 2012 On Thursday, February 28, 2013, After Close of U.S.-Based Financial Markets

PR Newswire (Feb 13, 2013)
Nektar Announces Initiation of Investigator-Initiated Trial Evaluating Etirinotecan Pegol (NKTR-102) as a Third-Line Treatment in Patients with Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC)

PR Newswire (Feb 5, 2013)
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA

PR Newswire (Jan 4, 2013)
AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation

PR Newswire (Nov 12, 2012)
Nektar To Host Conference Call To Discuss The Positive Phase 3 Clinical Results For Naloxegol

PR Newswire (Nov 12, 2012)
Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer

PR Newswire (Nov 7, 2012)
Nektar to Announce Financial Results for the Third Quarter of 2012 On Tuesday, November 13, 2012, After Close of U.S.-Based Financial Markets

PR Newswire (Nov 6, 2012)
Nektar Presents Positive Preclinical Data for NKTR-171, A Novel Sodium Channel Blocker to Treat Neuropathic Pain, at 41st Annual Meeting of the Society for Neuroscience

PR Newswire (Oct 15, 2012)
NKTR-192, A New Short-Acting Mu-Opioid Analgesic Molecule, Achieves Desired Pharmacokinetic Profile in First Phase 1a Clinical Study

PR Newswire (Sep 18, 2012)
Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the UBS 2012 Global Life Sciences Conference in New York City

PR Newswire (Sep 13, 2012)
Nektar Therapeutics Reports Financial Results for the Second Quarter of 2012

PR Newswire (Aug 9, 2012)
Nektar Announces Initiation of Investigator-Sponsored Trial Evaluating Etirinotecan Pegol (NKTR-102) in Patients with Bevacizumab (Avastin)-resistant High-Grade Glioma

PR Newswire (Aug 7, 2012)
Nektar to Announce Financial Results for the Second Quarter of 2012 On Thursday, August 9, 2012, After Close of U.S.-Based Financial Markets

PR Newswire (Aug 2, 2012)

NKTR vs. ETF Alternatives

Company Description

We are a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize our PEGylation and advanced polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Our current proprietary product pipeline is comprised of... More

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 9, 5:36 PM Nektar (NKTR): Q1 EPS of -$0.48 misses by $0.06. Revenue of $23M misses by $3.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 16, 7:25 AM Bayer initiates Phase III clinical trial of BAY41-6551, a treatment for Gram-negative pneumonia the company is developing with Nektar Therapeutics (NKTR). Comment! [Healthcare]
Thursday, February 28, 5:27 PM Nektar Therapeutics (NKTR): Q4 EPS of -$0.46 misses by $0.01. Revenue of $21.1M beats by $2.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, February 26, 8:31 AM AstraZeneca (AZN) says there were "no reports of opioid withdrawal" that could be attributed to its Naloxegol laxative in a fourth Phase III trial. AZN and partner Nektar Therapeutics (NKTR) will use the outcome to obtain decontrol of naloxegol, which is considered a Schedule II controlled substance by the DEA. With the testing demonstrating other "high-level" safety results, AstraZeneca plans to file for FDA and EU approval of Naloxegol in Q3. (PR) 1 Comment [Healthcare]
Monday, February 25, 7:28 AM Affymax (AFFY) prints at $3.41 premarket, -78.8%, following yesterday's report of the Omontys recall. AFFY has no other late-stage drugs in its pipeline. Piper expects shares to trade to cash value (~$2) "as investors take into account the lack of visibility." In play: AMGN, whose Epogen dominates the antianemia market (+2.4%), NKTR (which earns royalties on Omontys sales), and FMS, which pulled a trial two weeks ago (-1.3%). Comment! [Healthcare, On the Move]
Tuesday, January 15, 1:33 PM Nektar Therapeutics (NKTR +5.4%) gets a big boost out of Lazard Capital today, after it initiated the drug developer with a Buy rating and a price target of $15 a share. The company has a solid pipeline with a number of drugs on its docket, including Naloxegol, which has just finished Phase III testing, Cipro DPI with Bayer in Phase III and Baxter 855 and Amikacin Inhale preparing for Phase III. Royalties on these products alone are capable of generating over $750M a year. Comment! [Healthcare, On the Move]
Wednesday, January 9, 5:22 PM After-hours top gainers, as of 5:15 p.m.: VOXX +15%. NEWL +9%. SQNM +6%. PSMT +6%. XCO +6%.
After-hours top losers: QUIK -9%. RT -9%. HAFC -7%. NKTR -7%. HALO -7%. 1 Comment [On the Move]
Tuesday, November 13, 2012, 9:33 AM The Street's Adam Feuerstein wonders whether AstraZeneca's (AZN) and Nektar's (NKTR) critical naloxegol product for opioid-induced constipation failed one of its Phase III trials rather than passed it, as the companies indicate. Feuerstein's skepticism is based on AZN retrieving data from one patient that was thought to be non-retrievable after the database for the trial had been locked. 1 Comment [Healthcare]
Tuesday, November 13, 2012, 12:10 AM Notable earnings after Tuesday’s close: CSCO, GA, IAG, NKTR, RENN, SVM Comment! [Earnings]
Monday, November 12, 2012, 5:35 PM Notable earnings after Tuesday’s close: CSCO, GA, IAG, NKTR, RENN, SVM Comment! [Earnings]
Monday, November 12, 2012, 12:45 PM Midday top 10 gainers: TIE +42%. STV +32%. MYRX +18%. CPSS +17%. PZZI +15%. SRPT +13%. EVI +13%. JEF +12%. GILD +12%. CXS +12%. Midday top 10 Losers: CLVS -33%. GALE -33%. STSI -23%. RECV -17%. BZH -15%. ET -14%. XIDE -13%. NKTR -12%. MEET -12%. IDN -11%. Comment!
Monday, November 12, 2012, 10:04 AM Astrazeneca's (AZN) naloxegol product for treating opioid-induced constipation (OIC) performed well in two Phase III trials and one safety extension study. The trials also brought on no imbalances in serious adverse events. Astrazeneca acquired the worldwide licence for naloxegol from its developer, Nektar Therapeutics (NKTR -0.1%), in 2009. (PR) Comment! [Healthcare]
Monday, November 12, 2012, 9:10 AM Premarket gainers: TIE +43%. JEF +24%. MYRX +17%. CXS +15%. GILD +12%. CELG +10%. SVNT +7%. SQNM +7%. LUK +7%. RIMM +6%. NKTR +6%. STV +5%. DNDN +5%. CEL +5%. PCP +5%.
Losers: CLVS -41%. STSI -20%. NBG -11%. Comment! [On the Move]
Thursday, November 1, 2012, 12:10 AM Notable earnings after Thursday’s close: AIG, AIV, ALSK, ATML, BKD, BMR, CAR, CENX, CHK, DCT, DDR, DWA, EIX, EQIX, FLR, FSLR, GLUU, HAIN, HIG, HTGC, INT, ITMN, JMBA, JOE, KERX, KOG, LIFE, LLNW, LNC, LNKD, LVS, MDLZ, MELI, MNKD, NEM, NGD, NKTR, NLY, OMPI, ONNN, ONXX, OPEN, PBI, PCLN, ROVI, RSG, SAM, SBUX, SHO, SKUL, SPWR, SWKS, SWN, TRIP, UNTD, VNO, VRTX, WBMD, WIT, WPRT, YELP, ZAGG, ZIOP Comment! [Earnings]
Wednesday, October 31, 2012, 5:35 PM Notable earnings after Thursday’s close: AIG, AIV, ALSK, ATML, BKD, BMR, CAR, CENX, CHK, DCT, DDR, DWA, EIX, EQIX, FLR, FSLR, GLUU, HAIN, HIG, HTGC, INT, ITMN, JMBA, JOE, KERX, KOG, LIFE, LLNW, LNC, LNKD, LVS, MDLZ, MELI, MNKD, NEM, NGD, NKTR, NLY, OMPI, ONNN, ONXX, OPEN, PBI, PCLN, ROVI, RSG, SAM, SBUX, SHO, SKUL, SPWR, SWKS, SWN, TRIP, UNTD, VNO, VRTX, WBMD, WIT, WPRT, YELP, ZAGG, ZIOP Comment! [Earnings]
Tuesday, September 18, 2012, 10:17 AM Nektar Therapeutics (NKTR +2.1%) says that a Phase 1a clinical study of its drug candidate NKTR-192, a short-acting mu-opioid analgesic for the treatment of acute pain, achieved its target pharmacokinetic profile. The company also says that dosing has commenced in a second Phase 1a clinical study which will explore the pharmacodynamic profile of the drug in healthy subjects. Comment! [Healthcare, On the Move]

Jim Van Meerten
NKTR - 96% Barchart technical buy signal - 15 new highs and up 26.27% in the last month - Relative strength Index 77.91%
9/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Fast Growing Small Cap Biotech Stocks With Analyst Confidence http://bit.ly/Odu3LZ $EXAS $MACK $NKTR $THLD $CADX $SNTS $ACOR @ZetaKap
7/6/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

reachmygoals1
Nektar's(NKTR) upcoming catalysts: * NKTR-102 - Phase 2 expansion top-line data in ovarian cancer (April) * NKTR-181 - Phase 2 start
3/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

JINKANG
NKTR from Yahoo: Net loss for the second quarter ended June 30, 2011 was $36.4 million or $0.32 loss per share as compared to a net loss of
8/5/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

JINKANG
NKTR: Revenue for the second quarter of 2011 decreased to $17.3 million as compared to $42.6 million in the second quarter of 2010.
8/5/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
Sunday night watchlist http://stk.ly/p4wlWR AKRX BPAX EDR GLBL NKTR RAM VVUS ZIOP
7/24/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Ryan Mallory
5 Trade Setups While Waiting For The Market To Do Something http://stk.ly/pcW4WG BEBE GMO LIOX MHGC NKTR
7/20/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Smart-Ticker.com
Top stocks bear trade ideas $CML $NKTR $PTY $MGLN more http://s-t.cc
12/13/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Joshua Hayes
Other strong stocks with nice chart patterns in my long scan today: FTLK FTNT AFOB TAL AERG GIII LOCM SRPT NKTR SYNA SASR TDA SNCR HRL NEOG
7/26/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Inflection Point Investing LLC
Relative price strength in biotechs. Best looking charts include REGN, MITI, INCY, NKTR, DNDN, PCYC, VRUS, MAPP & UTHR
2/14/10
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

NKTR Nektar Therapeutics

NKTR

Nektar Therapeutics